PMID- 15500402
OWN - NLM
STAT- MEDLINE
DCOM- 20051209
LR  - 20191026
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 4
IP  - 11
DP  - 2004 Nov
TI  - Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.
PG  - 1735-47
AB  - Dendritic cells (DCs) are antigen-presenting cells that play an important role in 
      the body's immune defence against cancer. Strategies using antigen-primed DCs as 
      tumour vaccines show promise in patients, but the approach is cumbersome to use 
      clinically. Soluble tumour antigens can be targeted to DCs in vivo, but this 
      often induces antigenic tolerance rather than immunity. Liposomes are vesicular 
      lipid structures with adjuvant-like properties. Importantly, liposomes can 
      encapsulate antigen and immunomodulatory factors, thus serving as potent delivery 
      vehicles. Different strategies are being explored to target liposomal antigens to 
      DCs in vivo. One approach has employed single-chain antibody fragments to the DC 
      surface molecules CD11c and DEC-205, attached to the vesicle surface by 
      metal-chelating linkage, to target liposomal membranes containing antigen and 
      either interferon-gamma or lipopolysaccharide to DCs. Such membranes induce 
      dramatic antitumour responses and immunotherapeutic effects when used as a 
      vaccine in the murine tumour model B16-OVA melanoma. Liposomal targeting of 
      antigen and maturation signals directly to DCs in vivo, therefore, represents a 
      much simpler strategy for cancer immunotherapy than antigen loading DCs ex vivo.
FAU - Altin, Joseph G
AU  - Altin JG
AD  - The Australian National University, School of Biochemistry and Molecular Biology, 
      Faculty of Science, Canberra, ACT 0200, Australia. Joseph.Altin@anu.edu.au
FAU - van Broekhoven, Christina L
AU  - van Broekhoven CL
FAU - Parish, Christopher R
AU  - Parish CR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Chelating Agents)
RN  - 0 (Cytokines)
RN  - 0 (Drug Carriers)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Lipids)
RN  - 0 (Liposomes)
RN  - 0 (Vaccines, DNA)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - PHA4727WTP (Mannose)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Animals
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/*administration & dosage/immunology
MH  - Cancer Vaccines
MH  - Chelating Agents/administration & dosage
MH  - Cytokines/administration & dosage
MH  - Dendritic Cells/drug effects/*immunology
MH  - Drug Administration Routes
MH  - Drug Carriers
MH  - Drug Delivery Systems
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology/therapeutic use
MH  - Humans
MH  - Immune Tolerance
MH  - Immunity, Cellular
MH  - Immunoglobulin Fc Fragments/administration & dosage/immunology
MH  - *Immunotherapy, Adoptive
MH  - Lipids/chemistry
MH  - Liposomes/administration & dosage/immunology/pharmacokinetics
MH  - Lymphocyte Activation
MH  - Mannose/pharmacokinetics
MH  - Mice
MH  - Models, Immunological
MH  - Neoplasms/*immunology
MH  - T-Lymphocyte Subsets/immunology
MH  - Vaccines, DNA/administration & dosage
RF  - 112
EDAT- 2004/10/27 09:00
MHDA- 2005/12/13 09:00
CRDT- 2004/10/27 09:00
PHST- 2004/10/27 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2004/10/27 09:00 [entrez]
AID - EBT041103 [pii]
AID - 10.1517/14712598.4.11.1735 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2004 Nov;4(11):1735-47. doi: 10.1517/14712598.4.11.1735.